Celera Genomics
Quick Summary
Celera Genomics was an American company founded by J. Craig Venter in 1998. It played a significant role in the Human Genome Project (HGP) by employing a rapid sequencing technique called whole genome shotgun sequencing. This approach allowed Celera to decode DNA sections quickly, contributing to the completion of a rough draft of the human genome in 2000, alongside the publicly funded HGP. Celera also sequenced the genomes of other organisms, including the rat, mouse, and fruit fly. The company's work, particularly its rapid sequencing methods, advanced the field of genomics and contributed to the development of personalized medicine and forensic science.12
Ask Britannica AI about this topic
Britannica doesn't have a full article on this topic, so we've curated a list of our relevant coverage.
Francis Collins…questioned when a rival operation, Celera Genomics, emerged in 1998 and appeared to be working even faster than the HGP at deciphering the human deoxyribonucleic acid (DNA) sequence. Headed by American geneticist and businessman J. Craig Venter, a former NIH scientist, Celera had devised its own, quicker method—though some scientists,…
Read More…questioned when a rival operation, Celera Genomics, emerged in 1998 and appeared to be working even faster than the HGP at deciphering the human deoxyribonucleic acid (DNA) sequence. Headed by American geneticist and businessman J. Craig Venter, a former NIH scientist, Celera had devised its own, quicker method—though some scientists,…
Read More- Human Genome ProjectTimeline of the HGP
In 1998 a private-sector enterprise, Celera Genomics, headed by American biochemist and former NIH scientist J. Craig Venter, began to compete with and potentially undermine the publicly funded HGP. At the heart of the competition was the prospect of gaining control over potential patents on the genome sequence, which was…
Read MoreIn 1998 a private-sector enterprise, Celera Genomics, headed by American biochemist and former NIH scientist J. Craig Venter, began to compete with and potentially undermine the publicly funded HGP. At the heart of the competition was the prospect of gaining control over potential patents on the genome sequence, which was…
Read More
